1-10 of 10
Barbara Sleight
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Population Pharmacokinetics of Inotuzumab Ozogamicin (InO) As Single Agent in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia - Results from the ITCC-059 Phase IA and Phase II Trial

Edoardo Pennesi, Erica Brivio, Kathleen B. Pelletier, Ying Chen, Alwin D.R. Huitema, Yilin Jiang, Anneke C.J. Ammerlaan, Barbara Sleight, Franco Locatelli, Inge M. Van Der Sluis, Claudia Rossig, Christiane Chen-Santel, Bella Bielorai, Arnaud Petit, Jan Stary, Lucie Sramkova, Cristina Díaz de Heredia Rubio, Susana Rives, Aengus O'Marcaigh, Carmelo Rizzari, Gernot Engstler, Karsten Nysom, Alba Rubio-San-Simón, Francisco J. Bautista Sirvent, Bénédicte Bruno, Yives Bertrand, Benoit Brethon, Fanny Rialland, Genevieve Plat, Uta Dirksen, May Garrett, Christian M. Zwaan
Journal: Blood
Blood (2022) 140 (Supplement 1): 8845–8847.
https://doi.org/10.1182/blood-2022-165954
Published: 2022
Journal Articles

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Edoardo Pennesi, Erica Brivio, Anneke C.J. Ammerlaan, Yilin Jiang, Vincent H.J. van der Velden, Berna Beverloo, Barbara Sleight, Susana Rives, Cristina Díaz de Heredia Rubio, Francisco J. Bautista Sirvent, Alba Rubio-San-Simón, Fanny Rialland, Carmelo Rizzari, Bella Bielorai, Arnaud Petit, Bénédicte Bruno, Ingrid Øra, Anna Nilsson, Gernot Engstler, Claudia Rossig, Benoit Brethon, Franco Locatelli, Christian M. Zwaan
Journal: Blood
Blood (2022) 140 (Supplement 1): 8976–8978.
https://doi.org/10.1182/blood-2022-163056
Published: 2022
Journal Articles

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Clinical Trials & Observations
Erica Brivio, Franco Locatelli, Marta Lopez-Yurda, Andrea Malone, Cristina Díaz-de-Heredia, Bella Bielorai, Claudia Rossig, Vincent H. J. van der Velden, Anneke C. J. Ammerlaan, Adriana Thano, Inge M. van der Sluis, Monique L. den Boer, Ying Chen, Barbara Sleight, Benoit Brethon, Karsten Nysom, Lucie Sramkova, Ingrid Øra, Luciana Vinti, Christiane Chen-Santel, Christian Michel Zwaan
Journal: Blood
Blood (2021) 137 (12): 1582–1590.
https://doi.org/10.1182/blood.2020007848
Published: 2021
Includes: Supplemental data
Journal Articles

A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study

Erica Brivio, MD, Franco Locatelli, MD, Adriana Thano, Arnaud Petit, MD PhD, Britta Julia Vormoor, MD, Susana Rives, Bella Bielorai, MD, Claudia Rossig, Carmelo Rizzari, Vincent H.J. Van Der Velden, PhD, Anneke C.J. Ammerlaan, Monique L. Den Boer, PhD, Barbara Sleight, MD, Gernot Engstler, Jan Stary, MD PhD, Francisco José Bautista Sirvent, MD PhD, Christiane Chen-Santel, Bénédicte Bruno, MD, Yves Bertrand, MD, Fanny Rialland, MD, Geneviève Plat, Dirk Reinhardt, MD, Luciana Vinti, MD, Arend von Stackelberg, MD, Christian Michel Zwaan
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-134774
Published: 2020
Journal Articles

Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD PhD, Elias Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, MD, Erik R. Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, PhD, Anjali S. Advani, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1344.
https://doi.org/10.1182/blood-2019-122097
Published: 2019
Journal Articles

A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 Study

Erica Brivio, MD, Marta Lopez-Yurda, PhD, Cormac Ownes, MD, Cristina Díaz de Heredia, MD PhD, Bella Bielorai, MD, Claudia Rossig, Vincent van der Velden, PhD, Anneke C.J. Ammerlaan, Inge M. van der Sluis, MD PhD, Monique L. Den Boer, PhD, Ying Chen, Barbara Sleight, MD, Benoit Brethon, MD, Karsten Nysom, Jan Stary, Prof., MD PhD, Ingrid Øra, Christiane Chen-Santel, Luciana Vinti, MD, Franco Locatelli, MD PhD, Christian Michel Zwaan, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2629.
https://doi.org/10.1182/blood-2019-122411
Published: 2019
Journal Articles

Comparison of CD22 Expression between Baseline, End of Treatment, and Relapse Among Patients Treated with Inotuzumab Ozogamicin Who Responded and Subsequently Relapsed in Two Clinical Trials

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, Katherine F Liau, Kevin Nguyen, Barbara Sleight, Erik Vandendries, MD PhD, Alexander Neuhof, MD, A. Douglas Laird, Anjali S. Advani, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2699.
https://doi.org/10.1182/blood-2018-99-110826
Published: 2018
Journal Articles

Inotuzumab Ozogamicin (InO) Vs Standard of Care (SC) in Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL): Long-Term Results of the Phase 3 INO-VATE Study

Hagop M. Kantarjian, MD, Daniel J. DeAngelo, MD, Matthias Stelljes, MD, Michaela Liedtke, MD, Wendy Stock, MD, Nicola Goekbuget, MD, Susan M. O'Brien, MD, Elias J. Jabbour, MD, Tao Wang, PhD, Jane Liang White, ScD, Barbara Sleight, Erik Vandendries, MD PhD, Anjali S. Advani, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2574.
https://doi.org/10.1182/blood.V130.Suppl_1.2574.2574
Published: 2017
Journal Articles

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level

Hagop M. Kantarjian, MD, Wendy Stock, MD, Ryan D. Cassaday, MD, Daniel J. DeAngelo, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Matthias Stelljes, MD, Tao Wang, PhD, Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, MD PhD, A. Douglas Laird, Anjali S. Advani, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1272.
https://doi.org/10.1182/blood.V130.Suppl_1.1272.1272
Published: 2017
Journal Articles

Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase

Anjali S. Advani, MD, Elias J. Jabbour, MD, Matthias Stelljes, Daniel J. DeAngelo, MD PhD, Michaela Liedtke, MD, Wendy Stock, MD, Nicola Gökbuget, MD, Susan O'Brien, MD, Kongming Wang, PhD, Tao Wang, PhD, M. Luisa Paccagnella, PhD, Barbara Sleight, MD, Erik Vandendries, MD PhD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2016) 128 (22): 5188.
https://doi.org/10.1182/blood.V128.22.5188.5188
Published: 2016